Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
bortezomib
i
Other names:
LDP 341, MG 341, MLN 341, NSC 681239, PS 341, JNJ-26866138, PS-341, PS 0341, PS0341, NSC681239, LDP-341, PS341, LDP341, MLN341, MLN-341, NSC-681239
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(90)
News
Trials
Company:
Generic mfg.
Drug class:
Proteasome inhibitor
Related drugs:
‹
ixazomib (31)
carfilzomib (18)
NPI-0052 (2)
MG132 (1)
AVA3996 (0)
CEP-18770 (0)
ONX 0912 (0)
ixazomib (31)
carfilzomib (18)
NPI-0052 (2)
MG132 (1)
AVA3996 (0)
CEP-18770 (0)
ONX 0912 (0)
›
Associations
(90)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + panobinostat
Sensitive: A1 - Approval
bortezomib + panobinostat
Sensitive
:
A1
bortezomib + panobinostat
Sensitive: A1 - Approval
bortezomib + panobinostat
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + bortezomib
Sensitive: A1 - Approval
rituximab + bortezomib
Sensitive
:
A1
rituximab + bortezomib
Sensitive: A1 - Approval
rituximab + bortezomib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
bortezomib
Sensitive: A1 - Approval
bortezomib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + bortezomib
Sensitive: A2 - Guideline
lenalidomide + bortezomib
Sensitive
:
A2
lenalidomide + bortezomib
Sensitive: A2 - Guideline
lenalidomide + bortezomib
Sensitive
:
A2
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + elotuzumab
Sensitive: A2 - Guideline
bortezomib + elotuzumab
Sensitive
:
A2
bortezomib + elotuzumab
Sensitive: A2 - Guideline
bortezomib + elotuzumab
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
rituximab + bortezomib
Sensitive: A2 - Guideline
rituximab + bortezomib
Sensitive
:
A2
rituximab + bortezomib
Sensitive: A2 - Guideline
rituximab + bortezomib
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Kaposi Sarcoma
No biomarker
Kaposi Sarcoma
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.